Since PI3K/AKT signaling pathway is one of the mechanisms underlying hormonal therapy resistance in advanced breast carcinoma, PI3K inhibitors were used in combination with fulvestrant or tamoxifen. This evidence concerns the gene PIK3CB and breast carcinoma.